Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Operating Leases (2019 - 2025)

Lifecore Biomedical, Inc. \De\ has reported Operating Leases over the past 7 years, most recently at $1.4 million for Q1 2025.

  • For Q1 2025, Operating Leases fell 71.78% year-over-year to $1.4 million; the TTM value through Feb 2025 reached $1.4 million, down 71.78%, while the annual FY2024 figure was $1.7 million, 82.19% down from the prior year.
  • Operating Leases for Q1 2025 was $1.4 million at Lifecore Biomedical, Inc. \De\, down from $7.4 million in the prior quarter.
  • Over five years, Operating Leases peaked at $17.9 million in Q1 2021 and troughed at $1.4 million in Q1 2025.
  • A 5-year average of $8.7 million and a median of $7.8 million in 2022 define the central range for Operating Leases.
  • Biggest five-year swings in Operating Leases: skyrocketed 32.96% in 2023 and later plummeted 82.19% in 2024.
  • Year by year, Operating Leases stood at $11.3 million in 2021, then crashed by 38.12% to $7.0 million in 2022, then soared by 32.96% to $9.3 million in 2023, then dropped by 20.47% to $7.4 million in 2024, then plummeted by 80.65% to $1.4 million in 2025.
  • Business Quant data shows Operating Leases for LFCR at $1.4 million in Q1 2025, $7.4 million in Q4 2024, and $4.8 million in Q3 2024.